Mucinous rectal adenocarcinoma and neoadjuvant therapy: Implications for surgical practice

Table 3 Impact of mucinous histology on surgical complexity and outcomes

Ref.	Surgical parameter	MAC	Non-MAC
Hugen et al[2], 2014; Lan et al[7], 2021	Mean tumor size (cm)	5.2-6.8	3.5-4.5
McCawley et al[23], 2016; Hugen et al[2], 2014	CRM positivity rate (%)	14-28	6-11
Hugen et al[2], 2014; Lan et al[7], 2021	Rate of T4 disease at presentation (%)	26-33	10-17
Lohsiriwat and Lohsiriwat[41], 2008; de Nes et al[39], 2021	Multivisceral resection requirement (%)	12-18	4-7
Lohsiriwat and Lohsiriwat[41], 2008	Mean operative time for extended resections (minute)	274 ± 73	157 ± 62
Lohsiriwat and Lohsiriwat[41], 2008	Median blood loss for extended resections (mL)	769 ± 549	203 ± 136
Pelvex Collaborative[40], 2019	Major complication rate (Clavien-Dindo ≥ III, %)	38%	NA
Pelvex Collaborative[40], 2019; Hendrick et al[38], 2025	R0 resection rate in extended resections (%)	~ 72	~ 88

Summary of comparative surgical parameters for mucinous adenocarcinoma (MAC) and non-MAC. Data include tumor size, frequency of T4 disease, rates of circumferential resection margin (CRM) positivity, requirement for multivisceral resection, operative time, blood loss, complication rates, and R0 (no residual disease at surgery) resection rates in extended resections. Figures are derived from comparative observational series and meta-analyses within populations with locally advanced rectal cancer. NA: Not available.